Advertisement

Diuretika

  • Hartmut Oßwald
  • Bernd Mühlbauer

Zusammenfassung

Von Diuretika werden hauptsächlich Thiazide und Schleifendiuretika verordnet während Aldosteronantagonisten mit weitem Abstand folgen. Schleifendiuretika sind weiterhin die dominierende Gruppe der Diuretika mit über 50% des Verordnungsvolumens. Thiazide werden zunehmend als Monopräparate eingesetzt während die Thiazidkombinationen mit kaliumsparenden Diuretika auf im Vergleich zu früher deutlich niedrigerem Niveau stagnieren. Der zunehmende Einsatz von Spironolacton bei chronischer Herzinsuffizienz hat sich fortgesetzt

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC et al (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289:2560–2571.PubMedCrossRefGoogle Scholar
  2. Cosin J, Diez J, TORIC investigators (2003): Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507–513.CrossRefGoogle Scholar
  3. Düsing R, Piesche L (1990): Second line therapy of congestive heart failure with torasemide. Prog Pharmacol Clin Pharmacol 8:105–120.Google Scholar
  4. Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F (1993): Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7(Suppl 1): 81–85.PubMedCrossRefGoogle Scholar
  5. Greger R (1995): Loop Diuretics. In: Greger R, Knauf H, Mutschier, E (eds): Handbook of Experimental Pharmacology: Diuretics, Vol 117. Springer-Verlag, Berlin, pp 221–274.Google Scholar
  6. Heidland A, Bahner U (1999): Diuretika. In: Paumgartner G (Hrsg): Therapie innerer Krankheiten, 9. Aufl., Springer-Verlag, Berlin Heidelberg New York, S. 1548–1564.Google Scholar
  7. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001): Open label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111: 513–520.PubMedCrossRefGoogle Scholar
  8. Noe LL, Vreeland MG, Pezzella SM, Trotter JP (1999): A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 21: 854–866.PubMedCrossRefGoogle Scholar
  9. Oßwald H, Albinus M (1993): Hagers Handbuch der Pharmazeutischen Praxis, Stoffe A-Z, 5. Aufl, Band 8: Indapamid. In: von Bruchhausen F et al (Hrsg): S. 534–537, Band 9: Spironolacton, S. 650–654, Band 9: Xipamid S. 1212–1215. Springer-Verlag, Berlin.Google Scholar
  10. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999): The effect of Spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717.PubMedCrossRefGoogle Scholar
  11. Scheen aJ, Vancrombreucq JC, Delarge J, Luyckx AS (1986): Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study. Eur J Clin Pharmacol 31(Suppl): 35–42.PubMedCrossRefGoogle Scholar
  12. Spannheimer A, Goertz A, Dreckmann-Behrendt B (1998): Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract 52: 467–471.PubMedGoogle Scholar
  13. Stauch M, Stiehl L (1990): Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure — a multicenter study. Prog Pharmacol Clin Pharmacol 8: 121–126.Google Scholar
  14. Stroupe KT, Forthofer MM, Brater DC, Murray MD (2000): Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics. 17:429–440.PubMedCrossRefGoogle Scholar
  15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium Channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997.CrossRefGoogle Scholar
  16. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995): Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 57: 601–609.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Hartmut Oßwald
    • 1
  • Bernd Mühlbauer
    • 2
  1. 1.Pharmakologisches Institut der UniversitätTübingen
  2. 2.Institut für Klinische PharmakologieBremen

Personalised recommendations